|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Pulse Transit Time and Blood Pressure Changes Following Auditory-e- voked Subcortical Arousal and Waking of Infants 显示文摘 | Barbara C Galland Evan Tan Bar J Taylor | 2007 | Sleep2007，30，7： | 1 |
| 2 | How relevant is breast cancer screening in the Asia/Pacific region显示文摘 | Tan SM Evans AJ Lam TP | 2007 | Breast2007，16，： | 1 |
| 3 | Chemically-assigned classification of aerosol mass spectra显示文摘 | TAN P V MALPICA O EVANS G J | 2002 | American Society for Mass Spectrometry2002，13，7： | 1 |
| 4 | p38 MAPK and beta-arrestin 2 mediate functional interactions between endogenousmicro-opioid and alpha2 A-adrenergic receptors in neurons显示文摘 | Tan M Walwyn W M Evans C J | 2009 | J Biol Chem2009，284，10： | 1 |
| 5 | Herbicidal inhibitors of amino acid biosynthes is and herbicide tolerant crops显示文摘 | Tan S Evans R Singh B | 2006 | Amino Acids2006，，30： | 1 |
| 6 | Herbicidal inhibitors of amino acid bios-ynthesis and herbicide-tolerant crops显示文摘 | Tan S Evans R Singh B | 2006 | Amino Acids2006，30，2： | 1 |
| 7 | p38 MAPK and 显示文摘 | Tan M Walwyn WM Evans CJ | 2009 | Journal of biological chemistry2009，284，10： | 1 |
| 8 | Herbicidal inhibitors of amino acid biosynthesis and herbicide-tolerant crops显示文摘 | Tan S Evans R Singh B | 2006 | Amino Acids2006，30，： | 1 |
| 9 | lmidazolinonetolerant Crops; History, Current Status and Future显示文摘 | TAN S EVANS R R DAHMER M L | 2005 | Pest Manag Sci2005，61，： | 1 |
| 10 | Imidazolinone-tolerant crops:history,current status and future显示文摘 | Tan S Evans RR Dahmer ML | | 0，，03： | 1 |
| 11 | Herbicidal inhibitors of amino acid biosynthesis and herbicide-tolerant crops显示文摘 | Tan S Evans R Singh B | 2006 | Amino Acids2006，30，： | 1 |
| 12 | Imidazolinone-tolerant crops:history,current status and future显示文摘 | Tan S Evans R R Dahmer M L | 2005 | Pest Manag Sci2005，61，： | 1 |
| 13 | Herbicidal inhibitors of amino acid biosynthesis and herbicide-tolerant crops显示文摘 | Tan S Evans R Singh B | 2006 | Amino Acids2006，30，： | 1 |
| 14 | Imidazolinone-tolerant crops:history,current status and future显示文摘 | Tan S Evans R R Dahmer M L | 2005 | Pest Management Science2005，61，： | 1 |
| 15 | Herbicidal inhibitors of amino acid biosynthesis and herbicide-tolerant crops显示文摘 | Tan S Evans R Singh B | 2006 | Amino Acids2006，30，2： | 1 |
| 16 | Imidazolinone-tolerant crops:history,current status and future显示文摘 | TAN S EVANS R R DAHMER M L | | 0，，： | 1 |
| 17 | Imidazolinone-tolerant Crops:History,Current Status and Future显示文摘 | Tans S Evans R R Dahmer M L | 2005 | Pest Manag Sci2005，61，： | 1 |
| 18 | Cardiovascular variability is/is not an index of autonomic control of circulation显示文摘 | Julien C Billman GE Cerutti S Piepoli MF Bernardi L Sleight P Cohen MA Tan CO Laude D Elstad M Toska K Evans JM Eckberg DL | 2006 | J Appl Physiol2006，101，2： | 1 |
| 19 | A retrospective Aliskiren and Losartan study in non-diabetic chronic kidney disease显示文摘AIM: To assess the efficacy of combined Aliskiren and Losartan vs high dose Losartan and Aliskiren alone in chronic kidney disease(CKD).METHODS: This is a retrospective study of 143 patients with non-diabetic CKD comparing combined Aliskiren(150 mg/d) with Losartan(100 mg/d) therapyvs High dose Angiotensin receptor blockers(ARB)(Losartan 200 mg/d) and the third group Aliskiren(150 mg/d) alone. This study involved only patient medical records. Entry criteria included those patients who had been treated with the above drugs for at least 36 mo within the 5 years period; other criteria included proteinuria of 1 g or more and or CKD Stage 3 at the start of the 36 mo period. The study utilised primary renal end points of estimated Glomerular Filtration Rate(e GFR) < 15 m L/min or end stage renal failure. RESULTS: Patients treated with high dose ARB compared to the other two treatment groups had significantly less proteinuria at the end of 36 mo(P < 0.007). All 3 groups had significant reduction of proteinuria(P < 0.043, P < 0.001). Total urinary protein was significantly different between the 3 groups over the 3-year study period(P = 0.008), but not e GFR. The changes in e GFR from baseline to each year were not significantly different between the 3 therapeutic groups(P < 0.119). There were no significant differences in the systolic and diastolic blood pressure between the 3 drug groups throughout the 3 years. The incidence of hyperkalemia(> 5.5 mmol/L) was 14.2%(7/49) in the Combined Aliskiren and ARB group, 8.7%(4/46) in the Aliskiren alone group and 6.3%(3/48) in the High dose ARB group(P < 0.001). CONCLUSION: This study in non-diabetic CKD patients showed that Combination therapy with Aliskiren and ARB was effective but was not safe as it was associated with a high prevalence of hyperkalaemia. | Keng-Thye Woo Hui-Lin Choong Kok-Seng Wong Han-Kim Tan Marjorie Foo Fook-Chong Stephanie Evan JC Lee Vathsala Anantharaman Grace SL Lee Choong-Meng Chan | 2013 | World Journal of Nephrology2013，2，4： | 1 |
| 20 | Imidazolinone - tolerant crops: history, current status and future 显示文摘 | Tan S Evans R R Dahmer M L et al | 2005 | Pest Mauag Sci2005，61，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员